Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.

Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.

Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1908-16. doi: 10.1007/s00259-011-1853-6. Epub 2011 Jun 9.

PMID:
21656246
2.

Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease: a quantitative analysis of clinical 82Rb PET/CT studies.

Fukushima K, Javadi MS, Higuchi T, Bravo PE, Chien D, Lautamäki R, Merrill J, Nekolla SG, Bengel FM.

J Nucl Med. 2012 Jun;53(6):887-93. doi: 10.2967/jnumed.111.099325. Epub 2012 May 4.

3.

Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.

Bravo PE, Pozios I, Pinheiro A, Merrill J, Tsui BM, Wahl RL, Bengel FM, Abraham MR, Abraham TP.

Am J Cardiol. 2012 Oct 1;110(7):1033-9. doi: 10.1016/j.amjcard.2012.05.038. Epub 2012 Jun 28.

4.

Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.

Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE.

J Cardiovasc Magn Reson. 2013 Sep 24;15:85. doi: 10.1186/1532-429X-15-85.

5.

Regadenoson pharmacologic rubidium-82 PET: a comparison of quantitative perfusion and function to dipyridamole.

Cullom SJ, Case JA, Courter SA, McGhie AI, Bateman TM.

J Nucl Cardiol. 2013 Feb;20(1):76-83. doi: 10.1007/s12350-012-9636-4. Epub 2012 Nov 28.

PMID:
23188625
6.

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA.

J Nucl Cardiol. 2007 Jul;14(4):514-20.

PMID:
17679059
7.

Effect of Outflow Tract Contributions to 82Rb-PET Global Myocardial Blood Flow Computations.

Van Tosh A, Reichek N, Palestro CJ, Nichols KJ.

J Nucl Med Technol. 2016 Jun;44(2):78-84. doi: 10.2967/jnmt.116.173005. Epub 2016 Mar 10.

8.

A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.

Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H.

Clin Pharmacokinet. 2006;45(12):1201-12.

PMID:
17112296
9.

Advances in pharmacologic stress agents: focus on regadenoson.

Johnson SG, Peters S.

J Nucl Med Technol. 2010 Sep;38(3):163-71. doi: 10.2967/jnmt.109.065581. Epub 2010 Aug 19. Review.

10.

Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.

Friedman M, Spalding J, Kothari S, Wu Y, Gatt E, Boulanger L.

J Med Econ. 2013;16(4):449-60. doi: 10.3111/13696998.2013.772057. Epub 2013 Feb 25.

PMID:
23363331
11.

Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.

Johnson NP, Gould KL.

JACC Cardiovasc Imaging. 2015 Apr;8(4):438-47. doi: 10.1016/j.jcmg.2014.11.016. Epub 2015 Mar 18.

12.

Comparison of clinical tools for measurements of regional stress and rest myocardial blood flow assessed with 13N-ammonia PET/CT.

Slomka PJ, Alexanderson E, Jácome R, Jiménez M, Romero E, Meave A, Le Meunier L, Dalhbom M, Berman DS, Germano G, Schelbert H.

J Nucl Med. 2012 Feb;53(2):171-81. doi: 10.2967/jnumed.111.095398. Epub 2012 Jan 6.

13.

Regadenoson.

Garnock-Jones KP, Curran MP.

Am J Cardiovasc Drugs. 2010;10(1):65-71. doi: 10.2165/10489040-000000000-00000.

PMID:
20063904
14.

Regadenoson in the detection of coronary artery disease.

Buhr C, Gössl M, Erbel R, Eggebrecht H.

Vasc Health Risk Manag. 2008;4(2):337-40. Review.

15.

Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.

Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, Sinusas AJ.

JACC Cardiovasc Imaging. 2009 Oct;2(10):1198-208. doi: 10.1016/j.jcmg.2009.06.013.

16.

Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging.

Hsiao E, Ali B, Blankstein R, Skali H, Ali T, Bruyere J Jr, Kwong RY, Di Carli MF, Dorbala S.

J Nucl Med. 2013 Oct;54(10):1748-54. doi: 10.2967/jnumed.113.120063. Epub 2013 Aug 12.

17.

Regadenoson: a new myocardial stress agent.

Al Jaroudi W, Iskandrian AE.

J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30. doi: 10.1016/j.jacc.2009.04.089. Review. Erratum in: J Am Coll Cardiol. 2009 Oct 20;54(17):1635.

18.

Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.

Palani G, Ananthasubramaniam K.

Cardiol Rev. 2013 Jan-Feb;21(1):42-8. doi: 10.1097/CRD.0b013e3182613db6. Review.

PMID:
22643345
19.

The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.

DiBella EV, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B, Adluru G, Priester T, Kuppahally S, Jiji R, McGann C, Litwin SE.

Int J Cardiovasc Imaging. 2012 Aug;28(6):1435-44. doi: 10.1007/s10554-011-9949-4. Epub 2011 Oct 4.

20.

Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging.

Chow BJ, Wong JW, Yoshinaga K, Ruddy TD, Williams K, deKemp RA, DaSilva J, Beanlands RS.

J Nucl Med. 2005 Jul;46(7):1095-101.

Supplemental Content

Support Center